Phathom Pharmaceuticals (PHAT) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 19, 2026, at 9:00 AM EDT, with virtual attendance available.

• Shareholders are encouraged to review proxy materials and vote by May 18, 2026.

Voting matters and shareholder proposals

• Election of three class I directors to serve until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve executive compensation (say-on-pay).

• Other business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Nominees for director positions include Steven Basta, Theodore R. Schroeder, and Mark Stenhouse.